TP53 and breast cancer: p28 preferentially enters MCF-7, T47D, MDA-MB-231, and ZR-75-1 human breast cancer cells ~2- to 3-fold greater than in MCF-10A (normal) cells, irrespective of hormonal or p53 status, and exerts anti-proliferative activity (41, 74).